GLP-1 comparisons cluster
this cluster is for one intent: choosing among GLP-1 options using efficacy, tolerability, and operational constraints.
decision dimensions that matter
- efficacy: absolute weight loss and durability
- safety: GI intolerance, escalation tolerance, contraindications
- adherence: weekly vs daily schedules, route preference
- cost/access: insurance, out-of-pocket, supply reliability
- evidence quality: pivotal RCTs, follow-up duration, subgroup fit
core comparison workflow
begin with the interactive GLP-1 comparison tool, then validate top options at the course level for mechanism and trial interpretation.
course-level deep dives
next best pages
references
- Wilding JPH, et al. NEJM 2021; semaglutide STEP-1 trial.
- Jastreboff AM, et al. NEJM 2022; tirzepatide SURMOUNT-1 trial.
- Pi-Sunyer X, et al. NEJM 2015; liraglutide weight-management trial.
- US FDA labeling and safety communications for GLP-1 receptor agonists.